CARLOS AURELIO SANTOS ARAGAO

Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 9 de 9
  • conferenceObject
    Venous Thromboembolism as an Initial Manifestation of COVID-19 in a Heart Transplant Patient
    (2021) DANTAS, R. C. Tourinho; LIRA, M.; BELFORT, D.; ARAGAO, C.; MURAD, C.; AVILA, M.; SEGURO, L.; MANGINI, S.; CAMPOS, I.; MARCONDES-BRAGA, F.; BACAL, F.
  • conferenceObject
    Early Antibody-Mediated Rejection in Non-Pre-Sensitized Heart Transplant Recipient
    (2021) LIRA, M. S.; BELFORT, D. Sa Pereira; DANTAS, R. Cavalcanti Tourinho; ARAGAO, C. Aurelio Santos; AVILA, M. Samuel; SEGURO, L.; MANGINI, S.; CAMPOS, I. Wozniak; MARCONDES-BRAGA, F.; BACAL, F.
  • conferenceObject
    Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease
    (2021) MARCONDES-BRAGA, F. G.; MURAD, C. M.; BELFORT, D. D.; DANTAS, R. C.; LIRA, M. S.; ARAGAO, C.; SICILIANO, R. F.; MANGINI, S.; SEGURO, L.; CAMPOS, I. W. de; AVILA, M. S.; BELLO, M. V.; BARONE, F.; STRABELLI, T. M.; GAIOTTO, F. A.; BACAL, F.
  • conferenceObject
    Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient
    (2021) BELFORT, D. S.; CAFEZEIRO, C. R.; FURLAN, D. A.; LIRA, M. S.; DANTAS, R. C.; ARAGAO, C. A.; CAMPOS, I. W.; AVILA, M. S.; MANGINI, S.; SEGURO, L. B.; MARCONDES-BRAGA, F. G.; BACAL, F.
  • conferenceObject
    Neurochagas: A Rare Case of Reactivation of Chagas Disease after Heart Transplantation
    (2021) ARAGAO, C. A.; CAMPOS, I. W.; DANTAS, R. T.; LIRA, M. T.; BELFORT, D. S.; MURAD, C. M.; AVILA, M. S.; SEGURO, L. F.; MANGINI, S.; STRABELLI, T. V.; BRAGA, F. M.; BACAL, F.
  • conferenceObject
    COVID-19 Complicating Perioperative Management of Left Ventricular Assist Device Implantation
    (2021) BELFORT, D. S.; BISELLI, B.; BRANDAO, S. M.; GOMES, B. R.; LIRA, M. S.; DANTAS, R. C.; ARAGAO, C. A.; GALAS, F. R.; GAIOTTO, F. A.; JATENE, F. B.; BOCCHI, E. A.; FERREIRA, S. M.
  • article 1 Citação(ões) na Scopus
    Transplantation for Chagas Heart Disease: a Comprehensive Review
    (2021) BACAL, Fernando; MURAD, Ciro Mancilha; ARAGAO, Carlos Aurelio dos Santos; CAMPOS, Iascara Wozniak de; SEGURO, Luis Fernando Bernal da Costa; AVILA, Monica Samuel; MANGINI, Sandrigo; GAIOTTO, Fabio Antonio; STRABELLI, Tania Varejao; MARCONDES-BRAGA, Fabiana G.
    Purpose of Review Chagas cardiomyopathy (CC) has a worse prognosis than other forms of cardiomyopathy and up to 10% of patients may progress to end-stage heart failure. In this article, we have performed a comprehensive literature review of heart transplantation (HT) for CC, including results after HT, management of immunosuppression, and Chagas disease (CD) reactivation. Recent Findings CD used to be considered a contraindication to HT due to the risks of disease reactivation with immunosuppression. Nonetheless, multiple reports have consistently demonstrated the feasibility and safety of HT for refractory CC. CD reactivation must be routinely screened in the first-year post-transplant, and in recent years, polymerase chain reactions (PCR)-based techniques have been used more often. HT is now considered the best treatment for end-stage Chagas heart disease. In addition, studies of immunosuppressive medications have shown that these patients require a lesser degree of immunosuppression, mainly to balance reactivation risks.
  • conferenceObject
    Change in the Clinical-Demographic Profile of Chagasic Patients Who are Candidates for Heart Transplantation in Recent Years
    (2021) ARAGAO, C. A.; CAMPOS, I. W.; LIRA, M. T.; DANTAS, R. T.; MURAD, C. M.; BELFORT, D. S.; MANGINI, S.; STRABELLI, T. V.; BRAGA, F. M.; SEGURO, L. F.; AVILA, M. S.; GAIOTTO, F. A.; BACAL, F.
  • article 16 Citação(ões) na Scopus
    Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center
    (2022) MARCONDES-BRAGA, Fabiana G.; MURAD, Ciro M.; BELFORT, Deborah S. P.; DANTAS, Rafael C. T.; LIRA, Maria Tereza S. S.; ARAGAO, Carlos A. S.; SICILIANO, Rinaldo F.; MANGINI, Sandrigo; SEGURO, Luis Fernando B. C.; CAMPOS, Iascara W.; AVILA, Monica S.; BELLO, Mariana V. O.; SANTOS, Fernanda B. A. dos; V, Tania M. Strabelli; GAIOTTO, Fabio A.; BACAL, Fernando
    Background. Heart transplant (HT) recipients may be at higher risk of acquiring SARS-CoV-2 infection and developing critical illness. The aim of this study is to describe characteristics and outcomes of HT recipients infected by SARS-COV-2, from a high-volume transplant center. Methods. We have described data of all adult HT recipients with confirmed coronavirus disease 2019 by RT-PCR in nasopharyngeal samples from April 5, 2020, to January 5, 2021. Outcomes and follow-up were recorded until February 5, 2021. Results. Forty patients were included. Twenty-four patients (60%) were men; the median age was 53 (40-60) y old; median HT time was 34 mo; and median follow-up time 162 d. The majority needed hospitalization (83%). Immunosuppressive therapy was reduced/withdrawn in the majority of patients, except from steroids, which were maintained. Seventeen patients (42.5%) were classified as having severe disease according to the ordinal scale developed by the World Health Organization Committee. They tended to have lower absolute lymphocyte count (P < 0.001) during follow-up when compared with patients with mild disease. Thirty-day mortality was 12.5%. However, a longer follow-up revealed increased later mortality (27.5%), with median time to death around 35 d. Bacterial nosocomial infections were a leading cause of death. Cardiac allograft rejection (10%) and ventricular dysfunction (12.5%) were also not negligible. Conclusions. Major findings of this study corroborate other cohorts' results, but it also reports significant rate of later events, suggesting that a strict midterm surveillance is advisable to HT recipients with coronavirus disease 2019.